about
How to calculate the dose of chemotherapyCarboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2Inhibitors of mTOR.Metformin in prostate cancer: two for the price of one.Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.Evidence for therapeutic drug monitoring of targeted anticancer therapies.Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.Clinical perspectives: practical insights from clinical experience with cabazitaxel in Australia.Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.Dose considerations for anti-cancer drugs in metastatic prostate cancer.The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study.Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.Treatment of a pancreatic tumour secreting parathyroid hormone related protein.Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma.Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study.CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
P50
Q24642872-19E5FACE-8408-4287-A5D9-E75BCCABE521Q33338669-73A1F348-1E13-453E-B369-13FB8763F28DQ33613644-1AECBCF1-3D84-4912-9669-7D417EB6084FQ33795058-F5C6E2DF-00C8-4212-8CAE-2739D6571628Q35212672-AED4E69B-0A00-47A9-AD94-9FC04FA128A8Q35678056-E2828EEB-DDFB-4CCB-90D4-6FEF0B2E6E9FQ36367614-874DC240-02DA-4292-BD23-0FC47C8D8DBFQ37030719-56E758D8-7014-46E3-8B9C-63AF1F8383D1Q37115871-E369B66D-602B-4ADC-9AAB-5292C5F758F8Q37207831-2845B3E4-9B03-409D-9DF1-392692F0156CQ37819463-C35F1531-30A6-419E-96C2-4A71CE149471Q37855307-B3AC4C13-6A7B-4A8F-8194-4B5262C80037Q37988590-BB6094C1-5F61-4798-A04E-549FCA1E3AD3Q38038581-66841AC9-B480-4003-984A-77F5D26CF728Q38196082-999CAA82-F168-41DE-9F1C-4A10FE0AEFA0Q38205964-B16EDECD-7C41-4D93-94A6-257C021FDF52Q38378068-B80F4FD8-03B7-4343-B45F-4C3D2B489340Q38412864-771C1B67-7E03-49CF-8CBD-D22A0069A819Q38664221-D9B24FF7-7A64-49F5-ABE2-F02DB42DBE34Q38761275-54F708E1-4E6D-4C48-A845-CC309F8BAEE0Q38937228-8A387491-6213-46F9-985C-94C0F9FC4011Q39254111-2CF998B0-798F-44A1-80A4-02C380A543FAQ39397948-472ADF06-E78C-4C81-BF51-3115F8A8E6CAQ40699989-49AA333D-971C-4A58-8FC8-4D1E0DC0CB62Q40732847-678C692A-31C0-4C4C-B0E4-B5359BB677E2Q41316099-3BACD39D-1588-497F-A3CE-3F3BFFDEDA20Q41899044-D4DC7E96-7721-4D85-A62C-8FE62A69C8C8Q41979947-A74281BC-F04C-4F6F-9BC9-37545FD2476CQ42373342-F920C654-91DC-49DE-A37B-B35FF4F596DDQ42376791-42FD873A-16E3-4784-98D7-0AC2A18ADB50Q42970164-31F7DE7D-EFF2-490B-8EC4-E610DE758876Q43174498-0C2C0352-3EE5-4E8C-83FE-A81952439410Q43644649-83DB8C63-245B-4BA3-A0ED-3FADF8A6DC8CQ43785021-B1DE3E78-76C6-4B33-B0E1-8CFAED929AFDQ43958207-DE28CA83-D953-4AE8-B235-85F1D4813A9EQ44013895-32C8A75D-14E4-4EE3-AE80-289D30350202Q44217092-44977D9F-A832-4203-8C36-E28EC3D65A34Q44435533-36AF3C66-1779-4F84-9B11-A294A581A132Q44578920-B1E656C3-6475-481D-AFCB-F6390CE0D600Q44922994-AD0CA524-1657-4DAE-B99F-72E46D49794E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Howard Gurney
@ast
Howard Gurney
@en
Howard Gurney
@es
Howard Gurney
@nl
Howard Gurney
@sl
type
label
Howard Gurney
@ast
Howard Gurney
@en
Howard Gurney
@es
Howard Gurney
@nl
Howard Gurney
@sl
prefLabel
Howard Gurney
@ast
Howard Gurney
@en
Howard Gurney
@es
Howard Gurney
@nl
Howard Gurney
@sl
P106
P1153
56051414500
P21
P31
P496
0000-0003-0217-5261